Choroidal Neovascularization Treatment Market: Market Size & Forecast 2026

Choroidal neovascularization treatment focuses on halting abnormal blood vessel formation beneath the retina, primarily through anti-VEGF (vascular endothelial growth factor) biologics administered via intravitreal injection. These therapies treat neovascular age-related macular degeneration and related retinal conditions, representing one of the highest-volume and highest-cost categories in ophthalmic medicine. While no formal government statistical agency publishes an exact commercial market size figure, the global therapeutic protein market used heavily in ophthalmology reached approximately $155.06 billion in 2025, with anti-VEGF drugs as a dominant component.

• •Primary treatment modality relies on intravitreal injections of anti-VEGF biologics targeting VEGF-driven abnormal blood vessel growth
• •The broader therapeutic protein market, encompassing anti-VEGF agents, reached $155.06 billion globally in 2025
• •Direct global annual spending on anti-VEGF therapies for retinal diseases exceeds $7.0 billion

The market is propelled by demographic shifts toward an older global population, as CNV and neovascular AMD are predominantly age-related conditions with rising incidence rates. Continued clinical innovation in extended-interval anti-VEGF formulations and novel drug delivery mechanisms also contributes to market expansion. Escalating healthcare spending on ophthalmic biologics and the chronic, treatment-intensive nature of CNV management ensure sustained demand across both developed and emerging healthcare systems.

• •Aging global population drives increasing prevalence of neovascular AMD and CNV, conditions strongly correlated with advancing age
• •Extended-release anti-VEGF formulations and emerging drug classes are expanding treatment options and patient adherence
• •Chronic, lifelong treatment regimens and rising healthcare utilization sustain long-term demand

The market is segmented primarily by drug type, including established anti-VEGF agents, emerging biosimilars, and novel therapeutic proteins under development. Geographic distribution is concentrated in North America and Europe, where advanced healthcare infrastructure, high treatment penetration, and greater availability of specialty biologics drive the largest revenue shares. Asia-Pacific is emerging as the fastest-growing regional market due to aging demographics, improving healthcare access, and growing adoption of anti-VEGF therapies across developing nations.

• •Market segments include first-generation and next-generation anti-VEGF drugs, biosimilar alternatives, and emerging protein-based therapies
• •North America commands the largest market share driven by high treatment rates and established biologics infrastructure
• •Asia-Pacific represents the fastest-growing region, fueled by aging populations and expanding healthcare access

What are the recent trends and outlook?

The market is projected to continue its 12.1% annual growth trajectory through the coming decade, supported by aging demographics and sustained clinical demand. Key trends include development of gene therapy and sustained-release implant technologies that could reduce the injection burden for patients, as well as combination therapies targeting anti-VEGF resistance. Economic pressures from public and private payers are driving efforts toward cost-effective treatment protocols and biosimilar adoption, while projections indicate that without interventions, the societal burden of neovascular AMD could grow substantially by mid-century.

• •Long-acting sustained-release formulations and gene therapies under investigation could transform treatment paradigms and reduce injection frequency
• •Combination therapy approaches aim to address anti-VEGF resistance, a significant clinical challenge in a subset of patients
• •Biosimilar adoption and public payer cost-containment measures are expected to influence pricing dynamics over the forecast horizon